VEEV vs HUBS: Veeva Systems vs HubSpot Stock Comparison: AI Score, Valuation, Performance and Upside
Veeva Systems is a vertical SaaS company with near-monopoly software lock-in in pharmaceutical commercial and regulatory operations, while HubSpot is a horizontal SMB CRM platform that uses a freemium model to attract small businesses. Veeva has higher switching costs and more durable competitive position; HubSpot has a much larger TAM but faces more competition.
VEEV vs HUBS is vertical life sciences SaaS with deep switching costs versus horizontal SMB CRM with freemium growth — Veeva wins if pharma Vault migration sustains high retention; HubSpot wins if multi-hub expansion compounds per-customer revenue across a large SMB installed base.
VEEV holds the edge across 3 of 5 key metrics in this comparison. VEEV has delivered stronger 1-year price return (+1.60% vs -45.27%), though HUBS has the better forward P/E setup (14.45x vs 27.54x for VEEV). On fundamentals, HUBS is growing revenue faster (19.80%), while VEEV maintains the higher operating margin (29.64%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for HUBS (+1.08%) than for VEEV (-5.87%).
- want a vertical SaaS company with near-monopoly switching costs in pharma
- prefer life sciences software whose compliance requirements create permanent workflow dependency
- value Veeva's high margins and consistent free cash flow from a captive customer base
- are comfortable with slower growth in exchange for exceptionally high retention rates
- prefer a large-TAM horizontal CRM with freemium customer acquisition at scale
- value multi-hub expansion as an efficient path to increase revenue per customer over time
- believe HubSpot's SMB focus is defensible against enterprise CRM competition in smaller business segments
- are comfortable with more competitive dynamics in exchange for a much larger addressable market
| Metric | VEEV | HUBS |
|---|---|---|
| AI score | 53.5 | 42.3 |
| AI rank | #283 | #861 |
| Latest close | $276.69 | $260.68 |
| 1M return | +33.08% | +3.81% |
| 6M return | +51.31% | -1.45% |
| 1Y return | +1.60% | -45.27% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VEEV | HUBS |
|---|---|---|
| 1Y ago | $10.16K (+1.6%) started 2025-08-28 | $5.4K (-46.0%) started 2025-08-29 |
| 5Y ago | $8.32K (-16.8%) started 2021-08-30 | $3.72K (-62.8%) started 2021-08-30 |
| 10Y ago | $71.55K (+615.5%) started 2016-08-29 | $46.3K (+363.0%) started 2016-08-29 |
Hypothetical — past performance does not guarantee future results.
| Metric | VEEV | HUBS |
|---|---|---|
| Market cap | $44.95B | $12.29B |
| Trailing P/E | 45.43 | 85.41 |
| Forward P/E | 27.54 | 14.45 |
| Price/Sales | 13.00 | 11.26 |
| EV/Revenue | 11.19 | 3.15 |
| Analyst target | $260.44 | $242.61 |
| Target upside | -5.87% | +1.08% |
| Metric | VEEV | HUBS |
|---|---|---|
| Revenue growth | 17.60% | 19.80% |
| Earnings growth | 39.50% | 968.10% |
| EPS growth | +39.50% | +968.10% |
| FCF margin | +36.37% | +19.33% |
| Operating margin | 29.64% | 4.87% |
| Profit margin | 29.34% | 4.26% |
| ROIC proxy | 14.42% | 7.89% |
| Return on equity | 14.42% | 7.89% |
| Dividend yield | 0.00% | N/A |
| Beta | 0.92 | 1.17 |
| Debt/equity | 2.04 | 14.30 |
| Current ratio | 5.46 | 1.38 |
| Quick ratio | 5.36 | 1.11 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | VEEV | HUBS |
|---|---|---|---|
| 1Y | Growth | +1.60% | -46.05% |
| CAGR | +1.60% | -46.16% | |
| Sharpe ratio | 0.14 | -0.55 | |
| Max drawdown | 50.55% | 67.44% | |
| Max daily drop | 9.77% | 19.10% | |
| Max wkly drop | 16.81% | 27.02% | |
| 5Y | Growth | -16.82% | -62.84% |
| CAGR | -3.62% | -17.98% | |
| Sharpe ratio | -0.01 | -0.14 | |
| Max drawdown | 54.74% | 80.02% | |
| Max daily drop | 16.24% | 19.10% | |
| Max wkly drop | 21.64% | 27.02% | |
| 10Y | Growth | +615.52% | +363.02% |
| CAGR | +21.76% | +16.57% | |
| Sharpe ratio | 0.59 | 0.47 | |
| Max drawdown | 55.69% | 80.02% | |
| Max daily drop | 16.24% | 19.10% | |
| Max wkly drop | 21.64% | 28.86% |
| Category | VEEV | HUBS |
|---|---|---|
| Company | Veeva Systems Inc. | HubSpot, Inc. |
| Sector | Technology | Technology |
| Industry | N/A | N/A |
| Core business | Vertical cloud software for the life sciences industry, providing CRM, regulatory content management, clinical data, and quality management applications. Veeva's Vault platform is the standard of care for pharmaceutical commercial and clinical operations. | CRM platform for marketing, sales, service, and operations primarily serving small and mid-size businesses. HubSpot's inbound marketing philosophy and freemium model attract SMBs that grow into paying multi-hub customers. |
| Investor focus | Vault platform migration and adoption, Clinical Data Cloud advancement, data and analytics revenue, and transition to industry cloud model. | Customer count growth, multi-hub adoption (Marketing Hub + Sales Hub + Service Hub), average contract value expansion, and operating margin improvement. |
- Vertical SaaS for pharma creates extremely deep switching costs — switching Veeva means replacing core commercial and regulatory workflows
- Life sciences industry regulation creates a constant demand for Veeva's compliance-centric applications
- Data cloud and analytics create upsell potential on top of core software with high incremental margins
- Freemium model creates a large top-of-funnel for customer acquisition that converts to paid plans as SMBs grow
- Multi-hub strategy increases revenue per customer as HubSpot adds Sales, Service, and Operations Hubs to Marketing Hub
- HubSpot's SMB market focus provides a massive addressable market that Salesforce and enterprise CRMs largely ignore
- Salesforce is developing a competing life sciences CRM that could threaten Veeva's commercial segment long-term
- Veeva's growth is tied to pharmaceutical industry R&D and commercial spending cycles
- Transition to Vault platform requires customer migrations that can be complex and time-consuming
- Microsoft Dynamics, Salesforce Essentials, and Monday CRM compete directly in the SMB CRM market
- Economic headwinds reduce SMB spending on software — HubSpot's growth is sensitive to SMB health
- AI-powered CRM from Salesforce and Microsoft could commoditize basic marketing automation features
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.